1.Belchior H, Lopes-Dos-Santos V, Tort AB, Ribeiro S: Increase in hippocampal theta oscillations during spatial decision making. Hippocampus 2014, 24(6):693–702.
2.Kahana MJ, Sekuler R, Caplan JB, Kirschen M, Madsen JR: Human theta oscillations exhibit task dependence during virtual maze navigation. Nature 1999, 399(6738):781–784.
3.Buzsaki G: Theta oscillations in the hippocampus. Neuron 2002, 33(3):325–340.
4.Hu MM, Yan XD, Zhang XM, Bai Y, Zhao F, Qi JS: [Application of wireless neuronal recording system in fear conditioning of Alzheimer’s disease mice - hippocampal Theta oscillation observation]. Sheng li xue bao: [Acta physiologica Sinica] 2018, 70(5):571–578.
5.Kilias A, Haussler U, Heining K, Froriep UP, Haas CA, Egert U: Theta frequency decreases throughout the hippocampal formation in a focal epilepsy model. Hippocampus 2018, 28(6):375–391.
6.Ge ML, Guo JD, Chen SH, Zhang JC, Fu XX, Chen YM: [Quantitative evaluation of inhibitory effects of epileptic spikes on theta rhythms in the network of hippocampal CA3 and entorhinal cortex in patients with temporal lobe epilepsy]. Sheng li xue bao: [Acta physiologica Sinica] 2017, 69(1):77–88.
7.Li X, Hou Y, Ren Y, Tian X, Song Y: Alterations of theta oscillation in executive control in temporal lobe epilepsy patients. Epilepsy research 2018, 140:148–154.
8.Konopacki J, MacIver MB, Bland BH, Roth SH: Carbachol-induced EEG ‘theta’ activity in hippocampal brain slices. Brain research 1987, 405(1):196–198.
9.Lu CB, Henderson Z: Nicotine induction of theta frequency oscillations in rodent hippocampus in vitro. Neuroscience 2010, 166(1):84–93.
10.Schiemann-Delgado J, Yang H, Loge Cde L, Stalvey TJ, Jones J, Legoff D, Mintz M: A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures. Journal of child neurology 2012, 27(1):80–89.
11.De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS drug reviews 2007, 13(1):57–78.
12.Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ et al: Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(42):E2895–2903.
13.Browning M, Shear DA, Bramlett HM, Dixon CE, Mondello S, Schmid KE, Poloyac SM, Dietrich WD, Hayes RL, Wang KK et al: Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of neurotrauma 2016, 33(6):581–594.
14.Zou H, Brayer SW, Hurwitz M, Niyonkuru C, Fowler LE, Wagner AK: Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury. Neurorehabilitation and neural repair 2013, 27(9):878–888.
15.Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT: Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocritical care 2006, 5(1):71–78.
16.West PJ, Saunders GW, Remigio GJ, Wilcox KS, White HS: Antiseizure drugs differentially modulate θ-burst induced long-term potentiation in C57BL/6 mice. Epilepsia 2014, 55(2):214–223.
17.Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M: Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment: Neuron. 2012 May 10;74(3):467–74. doi:10.1016/j.neuron.2012.03.023.; 2012.
18.Barker-Haliski ML, Vanegas F, Mau MJ, Underwood TK, White HS: Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice. Epilepsia 2016, 57(9):1386–1397.
19.Ge YX, Tian XZ, Lin YY, Liu XY: Chronic treatment with levetiracetam reverses deficits in hippocampal LTP in vivo in experimental temporal lobe epilepsy rats. Neuroscience letters 2016, 628:194–200.
20.Koh MT, Shao Y, Rosenzweig-Lipson S, Gallagher M: Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. Schizophrenia research 2017.
21.Garner HL, Whittington MA, Henderson Z: Induction by kainate of theta frequency rhythmic activity in the rat medial septum-diagonal band complex in vitro. The Journal of physiology 2005, 564(Pt 1):83–102.
22.Lu CB, Li CZ, Li DL, Henderson Z: Nicotine induction of theta frequency oscillations in rodent medial septal diagonal band in vitro. Acta pharmacologica Sinica 2013, 34(6):819–829.
23.Palhalmi J, Paulsen O, Freund TF, Hajos N: Distinct properties of carbachol- and DHPG-induced network oscillations in hippocampal slices. Neuropharmacology 2004, 47(3):381–389.
24.Oja SS, Saransaari P: Significance of Taurine in the Brain. Advances in experimental medicine and biology 2017, 975 Pt 1:89–94.
25.del Olmo N, Bustamante J, del Rio RM, Solis JM: Taurine activates GABA(A) but not GABA(B) receptors in rat hippocampal CA1 area. Brain Res 2000, 864(2):298–307.
26.Rigo J, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A et al: The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology 2002, 136(5):659–672.
27.Tong X, Patsalos PN: A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 2001, 133(6):867–874.
28.Gillies MJ, Traub RD, LeBeau FE, Davies CH, Gloveli T, Buhl EH, Whittington MA: A model of atropine-resistant theta oscillations in rat hippocampal area CA1. The Journal of physiology 2002, 543(Pt 3):779–793.
29.Pastukhov A, Borisova T: Levetiracetam-mediated improvement of decreased NMDA-induced glutamate release from nerve terminals during hypothermia. Brain research 2018, 1699:69–78.
30.Lee CY, Chen CC, Liou HH: Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus. British Journal of Pharmacology 2009, 158(7):1753–1762.
31.Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH: Differential expression of synaptic vesicle protein 2 (SV2) isoforms. The Journal of neuroscience: the official journal of the Society for Neuroscience 1994, 14(9):5223–5235.
32.Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM: Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Sciences of the United States of America 1999, 96(26):15268.
33.Furukawa T, Yamada J, Akita T, Matsushima Y, Yanagawa Y, Fukuda A: Roles of taurine-mediated tonic GABAA receptor activation in the radial migration of neurons in the fetal mouse cerebral cortex. Frontiers in Cellular Neuroscience 2014, 8:88.
34.Jia F, Yue M, Chandra D, Keramidas A, Goldstein PA, Homanics GE, Harrison NL: Taurine Is a Potent Activator of Extrasynaptic GABA<sub>A</sub> Receptors in the Thalamus. The Journal of Neuroscience 2008, 28(1):106–115.
35.Brickley SG, Mody I: Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron 2012, 73(1):23–34.
36.Wulfert E, Hanin I, Verloes R: Facilitation of calcium-dependent cholinergic function by ucb L059, a new “second generation” nootropic agent. Psychopharmacology bulletin 1989, 25(3):498–502.
37.Chauviere L, Rafrafi N, Thinus-Blanc C, Bartolomei F, Esclapez M, Bernard C: Early deficits in spatial memory and theta rhythm in experimental temporal lobe epilepsy. The Journal of neuroscience: the official journal of the Society for Neuroscience 2009, 29(17):5402–5410.
38.Csicsvari J, Jamieson B, Wise KD, Buzsaki G: Mechanisms of gamma oscillations in the hippocampus of the behaving rat. Neuron 2003, 37(2):311–322.